ESOU 2021: ESUR Lecture: Genetic Testing for Prostate Cancer: When and How?
(UroToday.com) At the 2021 European Association of Urology (EAU) Section of Oncological Urology (ESOU) Virtual Annual Meeting, the EAU Section of Urological Research (ESUR) lecture was provided by Dr. Karen Knudsen discussing when and how to provide genetic testing for prostate cancer. Dr. Knudsen pointed out that there is an extraordinary burden of prostate cancer in the US, ranked as #1 for males in estimated new cases and #2 in estimated cancer-related deaths. Germline testing is revolutionizing care, with 12-17% of metastatic patients having germline mutations and 5-7% of early-stage patients having germline mutations. As such, germline testing is impacting precision medicine and tailored screening approaches, which also has an impact on families for hereditary cancer risk.
Penn medicine patients like chemotherapy at home during COVID but the billing system limits all that inquirer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inquirer.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
METUCHEN, N.J., Jan. 25, 2021 /PRNewswire/ Tevogen Bio today announced it has secured necessary funding from HMP Partners of New Jersey, an investment firm managed by medical doctors, which will allow Tevogen to support all clinical trials of its investigational, potentially curative COVID-19 treatment. Tevogen s Investigational New Drug (IND) application for its proprietary antigen-specific T cell therapy is under review by the U.S. Food and Drug Administration (FDA).
All COVID-19 therapeutics utilized to date have sought to slow the progression of the infection and/or moderate its symptoms. These approaches buy time for the patient s own T cells to activate and respond to the infection, which is the mechanism that the body employs to rid itself of viruses such as the SARS-CoV-2.
Sidney Kimmel Cancer Center – Washington Township Welcomes New Surgeons January 14, 2021, 10:56 am | in
Sidney Kimmel Cancer Center – Washington Township Welcomes New Surgeons
Washington Township, NJ, January 12, 2021 –- Two highly trained breast surgeons have joined the Comprehensive Breast Center at the Sidney Kimmel Cancer Center – Washington Township:
Kristin Brill, MD, FACS –
Enterprise Director of Breast Oncology – is a graduate of Hahnemann University School of Medicine and completed her General Surgery Residency at New York Methodist Hospital, and her Breast Surgical Oncology Fellowship at New York Presbyterian/Columbia Medical Center. Board certified by the American Board of Surgery, Dr. Brill’s special interests include young women with breast cancer and those at high risk. She also holds special interest in breast conservation surgery, oncoplastic surgery, and skin-sparing mastectomy. Dr. Brill is a member of the America